medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-36-18-24medalphabet-2390Research ArticleНЕВРОЛОГИЯ И ПСИХИАТРИЯNEUROLOGY AND PSYCHIATRYЦентральные нежелательные реакции НПВСCentral adverse drug reactions of NSAIDsПереверзевА. П.PereverzevA. P.

Переверзев Антон Павлович, к. м. н., доцент кафедры терапии и полиморбидной патологии

Pereverzev Anton P., PhD Med, associate professor at Dept of Therapy andPolymorbid Pathology

Moscow

terapia_polimorbid@rmapo.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation202126122021036Неврология и психиатрия (4)1824Copyright © Переверзев А.П., 20212021Переверзев А.П.Pereverzev A.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2390

Нестероидные противовоспалительные средства (НПВС) – группа лекарственных средств (ЛС), применяемая с целью анальгезии, борьбы с воспалением, пирексией, а также обладающих в разной степени выраженности антиагрегантной активностью. НПВС широко применяются в лечении остеоартрита, скелетно-мышечной боли, подагры и других патологических состояний, однако прием этих лекарственных препаратов ассоциирован с риском развития нежелательных реакций, в том числе серьезных и с летальным исходом, например желудочно-кишечного кровотечения, развившегося на фоне гастро- или энтеропатии, инфаркта миокарда или инсульта. Многие представители НПВС могут также проникать через гематоэнцефалический барьер в центральную нервную систему и вызывать нежелательные реакции, которые по ошибке могут быть приняты специалистами практического здравоохранение за манифестацию нового или обострение (недостаточную эффективность лечения) уже имеющегося заболевания, но не ассоциироваться с приемом НПВС, что, в свою очередь, приведет к ошибкам в тактике лечения, дополнительному назначению ЛС и повышению риска развития осложнений. Целью данной статьи является информирование специалистов практического здравоохранения о потенциальных рисках развития НР со стороны центральной нервной системы (в том числе психиатрических), вызванных приемом НПВС, что, по мнению автора, будет способствовать повышению эффективности и безопасности терапии.

Non-steroidal anti-inflammatory drugs (NSAIDs) is a group of drugs used for analgesia, antinflammatory, antipyretical properties, and antiplatelet effects. NSAIDs are widely used in the treatment of osteoarthritis, musculoskeletal pain, gout and other pathological conditions, however, their use is associated with the risk of developing adverse drug reactions, including serious and fatal ones, for example, gastrointestinal bleeding, or myocardial infarction and stroke. Many NSAIDs can also cross the blood-brain barrier and cause central adverse drug reactions that can be mistaken by practical health care professionals for the manifestation of a new pathologies or insufficient effectiveness of treatment of an existing disease, but not with the use of NSAIDs, that may lead to errors in treatment tactics, additional prescription of drugs and an increased risk of complications. The purpose of this article is to inform practical health care professionals about the potential risks of central adverse drug reactions (including psychiatric ones) of NSAIDs, and thus, to increase the effectiveness and safety of therapy.

нестероидные противовоспалительные средстваНПВСнежелательные реакцийцентральная нервная системабезопасностьnon-steroidal anti-inflammatory drugsNSAIDsadverse drug reactionscentral nervous systemsafetyReferencesЕ. А. Ушкалова, С. К. Зырянов, А. П. Переверзев. Клиническая фармакология нестероидных противовоспалительных средств: Учеб. пособие. Москва: ООО «Медицинское информационное агентство», 2018. 368 с.: ил. + 12 с. цв. вкл.E. A. Ushkalova, S. K. Zyryanov, A. P. Clinical pharmacology of non-steroidal anti-inflammatory drugs: Textbook. Moscow: LLC «Medical Information Agency», 2018. 368 p.: ill. + 12 p. color incl.Алексеева Л. И., Таскина Е. А., Кашеварова Н. Г. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019; 13 (2): 9–21.Alekseeva L. I., Taskina E. A., Kashevarova N. G. Osteoarthritis: epidemiology, classification, risk factors and progression, clinical picture, diagnosis, treatment. Modern Rheumatology. 2019; 13 (2): 9–21.Официальный сайт Европейского общества по изучению клинических и экономических аспектов остеопороза, остеоартрита и мышечно-скелетных заболеваний (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, ESCEO). Available at: https://www.esceo.org (дата обращения 25.11.2021).European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Available at: https://www.esceo.org (date of access 25.11.2021).Официальный сайт Европейской лиги по борьбе с ревматизмом (European League Against Rheumatism, EULAR) Available at: https://www.eular.org (дата обращения 25.11.2021).European League Against Rheumatism (EULAR) Available at: https://www.eular.org (date of access 25.11.2021).Проект клинических рекомендаций «Диагностика и лечение скелетно-мышечных (неспецифических) болей в нижней части спины» Available at: https://painrussia.ru/publications/reference-materials-and-guides/БС_РОИБ_2020.pdf (дата обращения 25.11.2021).Draft clinical guidelines «Diagnosis and treatment of musculoskeletal (nonspecific) pain in the lower back» Available at: https://painrussia.ru/publications/reference-materials-and-guides/BS_ROIB_2020.pdf (date of access 25.11.2021).Клинические рекомендации «Подагра» (утв. Минздравом России) Available at: https://www.consultant.ru (дата обращения 25.11.2021).Clinical guidelines «Gout» (approved by the Ministry of Health of Russia) Available at: https://www.consultant.ru (date of treatment 11/25/2021).А. П. Переверзев, О. Д. Остроумова. Лекарственно-индуцированные поражения желудочно-кишечного тракта. Часть 1. Типы и патофизиологические механизмы поражения. Терапия. 2020; 6: 171–183. DOI: https://dx.doi.org/10.18565/therapy.2020.6.171–183A. P. Pereverzev, O. D. Ostroumova. Drug-induced lesions of the gastrointestinal tract. Part 1. Types and pathophysiological mechanisms of damage. Therapy. 2020; 6: 171–183. DOI: https://dx.doi.org/10.18565/therapy.2020.6.171–183Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P. M., Egger M., Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011, Jan 11; 342: c7086. DOI: 10.1136/bmj.c7086.Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P. M., Egger M., Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011, Jan 11; 342: c7086. DOI: 10.1136/bmj.c7086.Thöne K., Kollhorst B., Schink T. Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study. Drugs Real World Outcomes. 2017 Sep; 4 (3): 127–137. DOI: 10.1007/s40801–017–0113-x.Thöne K., Kollhorst B., Schink T. Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study. Drugs Real World Outcomes. 2017 Sep; 4 (3): 127–137. DOI: 10.1007/s40801–017–0113-x.Mahajan N. S., Mahajan R., Mittal R. NSAID induced hypomania in stable bipolar disorder. Indian J Psychiatry. 2012; 54 (3): 293. DOI: 10.4103/0019–5545.102452.Mahajan N. S., Mahajan R., Mittal R. NSAID induced hypomania in stable bipolar disorder. Indian J Psychiatry. 2012; 54 (3): 293. DOI: 10.4103/0019–5545.102452.Herpfer I., Lieb K. Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential. CNS Drugs 2005; 19: 275–93.Herpfer I., Lieb K. Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential. CNS Drugs 2005; 19: 275–93.Iftikhar K., Siddiq A., Baig S. G., Zehra S. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders. Neuropeptides. 2020 Feb; 79: 101993. DOI: 10.1016/j.npep.2019.101993.Iftikhar K., Siddiq A., Baig S. G., Zehra S. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders. Neuropeptides. 2020 Feb; 79: 101993. DOI: 10.1016/j.npep.2019.101993.Vellani V., Franchi S., Prandini M., Moretti S., Castelli M., Giacomoni C., Sacerdote P. Effects of NSAIDs and paracetamol (acetaminophen) on protein kinase C epsilon translocation and on substance P synthesis and release in cultured sensory neurons. J Pain Res. 2013; 6: 111–20. DOI: 10.2147/JPR.S 36916.Vellani V., Franchi S., Prandini M., Moretti S., Castelli M., Giacomoni C., Sacerdote P. Effects of NSAIDs and paracetamol (acetaminophen) on protein kinase C epsilon translocation and on substance P synthesis and release in cultured sensory neurons. J Pain Res. 2013; 6: 111–20. DOI: 10.2147/JPR.S 36916.Jin-Li Guo, Yi-Ting Yue, Hong Cheng, Yong-Bo Huang, Wen-Bin Li, Xian-Yan Yan, Chao-Na Gao, Xiu-Juan Guo. The effects of three kinds of non-steroidal anti-inflammatory drugs on postoperative pain and on the serum levels of tumour necrosis factor-α and substance P in paediatric patients following orthopaedic hip surgery. Archives of Medical Science. 2020. DOI: 10.5114/aoms.2020.96992.Jin-Li Guo, Yi-Ting Yue, Hong Cheng, Yong-Bo Huang, Wen-Bin Li, Xian-Yan Yan, Chao-Na Gao, Xiu-Juan Guo. The effects of three kinds of non-steroidal anti-inflammatory drugs on postoperative pain and on the serum levels of tumour necrosis factor-α and substance P in paediatric patients following orthopaedic hip surgery. Archives of Medical Science. 2020. DOI: 10.5114/aoms.2020.96992.Young L. T., Bezchlibnyk Y. B., Chen B., Wang J. F., MacQueen G. M. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: Effects of diagnosis, suicide, and drug treatment. Biol Psychiatry. 2004; 55: 570–7.Young L. T., Bezchlibnyk Y. B., Chen B., Wang J. F., MacQueen G. M. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: Effects of diagnosis, suicide, and drug treatment. Biol Psychiatry. 2004; 55: 570–7.Arnao V., Riolo М., Fierro В., Arido Р. Seizure following the Use of the COX-2 Inhibitor Etoricoxib. Hindawi. Case Reports in Neurological Medicine. Volume 2017, Article ID 1410759, 3 pages. https://doi.org/10.1155/2017/1410759Arnao V., Riolo М., Fierro В., Arido Р. Seizure following the Use of the COX-2 Inhibitor Etoricoxib. Hindawi. Case Reports in Neurological Medicine. Volume 2017, Article ID 1410759, 3 pages. https://doi.org/10.1155/2017/1410759Sánchez-Hernandez M.C., Delgado J., Navarro A. M., Orta J. C., Hernandez M., Conde J. Seizures induced by NSAID. Allergy. 1999 Jan; 54 (1): 90–1. DOI: 10.1034/j.1398–9995.1999.00931.x.Sánchez-Hernandez M.C., Delgado J., Navarro A. M., Orta J. C., Hernandez M., Conde J. Seizures induced by NSAID. Allergy. 1999 Jan; 54 (1): 90–1. DOI: 10.1034/j.1398–9995.1999.00931.x.Reynolds J. E. Mefenamic acid. In: Martindale: the extra pharmacopoeia. London: Pharmaceutical Press, 1982: 262–263.Reynolds J. E. Mefenamic acid. In: Martindale: the extra pharmacopoeia. London: Pharmaceutical Press, 1982: 262–263.Hoppman A., Peden J. G., Ober S. K. Central nervous system side effects of nonsteroidal antiin-ammatory drugs. Arch Intern Med 1991; ISI: 1309–1313.Hoppman A., Peden J. G., Ober S. K. Central nervous system side effects of nonsteroidal antiin-ammatory drugs. Arch Intern Med 1991; ISI: 1309–1313.Sanchez-Valiente S. Encefalopatia mioclonica originada por el tratamiento con Diclofenac. Rev Neurol 1995; PQ: 1226–1227.Sanchez-Valiente S. Encefalopatia mioclonica originada por el tratamiento con Diclofenac. Rev Neurol 1995; PQ: 1226–1227.Reid E., Winnicka L., Chawla S., Thomas S. V. NSAID-Induced Seizures After an Intentional Overdose. Am J Respir Crit Care Med 2019; 199: A4836Reid E., Winnicka L., Chawla S., Thomas S. V. NSAID-Induced Seizures After an Intentional Overdose. Am J Respir Crit Care Med 2019; 199: A4836Sylvia L. M., Forlenza S. W., Brocavich J. M. Aseptic meningitis associated with naproxen [letter]. Drug Intell Clin Pharm 1988; 22: 399–401.Sylvia L. M., Forlenza S. W., Brocavich J. M. Aseptic meningitis associated with naproxen [letter]. Drug Intell Clin Pharm 1988; 22: 399–401.Weksler B. B., Lehany A. M. Naproxen-induced recurrent aseptic meningitis. Drug Intell Clin Pharm 1991; 25: 1183–4.Weksler B. B., Lehany A. M. Naproxen-induced recurrent aseptic meningitis. Drug Intell Clin Pharm 1991; 25: 1183–4.Peck M. G., Joyner P. U. Ibuprofen-associated aseptic meningitis. Clin Pharm. 1982 Nov-Dec; 1 (6): 561–5.Peck M. G., Joyner P. U. Ibuprofen-associated aseptic meningitis. Clin Pharm. 1982 Nov-Dec; 1 (6): 561–5.Bernstein R. F. Ibuprofen-related meningitis in mixed connective tissue disease. Ann Intern Med. 1980 Feb; 92 (2 Pt 1): 206–7. DOI: 10.7326/0003–4819–92–2–206.Bernstein R. F. Ibuprofen-related meningitis in mixed connective tissue disease. Ann Intern Med. 1980 Feb; 92 (2 Pt 1): 206–7. DOI: 10.7326/0003–4819–92–2–206.Giansiracusa D. F., Blumberg S., Kantrowitz F. G. Aseptic meningitis associated with ibuprofen. Arch Intern Med. 1980 Nov; 140 (11): 1553.Giansiracusa D. F., Blumberg S., Kantrowitz F. G. Aseptic meningitis associated with ibuprofen. Arch Intern Med. 1980 Nov; 140 (11): 1553.Finch W. R., Strottman M. P. Acute adverse reactions to ibuprofen in systemic lupus erythematosus. JAMA. 1979 Jun 15; 241 (24): 2616–8.Finch W. R., Strottman M. P. Acute adverse reactions to ibuprofen in systemic lupus erythematosus. JAMA. 1979 Jun 15; 241 (24): 2616–8.Samuelson C. O. Jr, Williams H. J. Ibuprofen-associated aseptic meningitis in systemic lupus erythematosus. West J Med. 1979 Jul; 131 (1): 57–9.Samuelson C. O. Jr, Williams H. J. Ibuprofen-associated aseptic meningitis in systemic lupus erythematosus. West J Med. 1979 Jul; 131 (1): 57–9.Wasner C. K. Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol. 1978 Summer; 5 (2): 162–4.Wasner C. K. Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol. 1978 Summer; 5 (2): 162–4.Widener H. L., Littman B. H. Ibuprofen-induced meningitis in systemic lupus erythematosus. JAMA. 1978 Mar 13; 239 (11): 1062–4.Widener H. L., Littman B. H. Ibuprofen-induced meningitis in systemic lupus erythematosus. JAMA. 1978 Mar 13; 239 (11): 1062–4.Bouland D. L., Specht N. L., Hegstad D. R. Ibuprofen and aseptic meningitis. Ann Intern Med. 1986 May; 104 (5): 731. DOI: 10.7326/0003–4819–104–5–731_1.Bouland D. L., Specht N. L., Hegstad D. R. Ibuprofen and aseptic meningitis. Ann Intern Med. 1986 May; 104 (5): 731. DOI: 10.7326/0003–4819–104–5–731_1.Perera D. R., Seiffert A. K., Greeley H. M. Ibuprofen and meningoencephalitis. Ann Intern Med. 1984 Apr; 100 (4): 619. DOI: 10.7326/0003–4819–100–4–619_2.Perera D. R., Seiffert A. K., Greeley H. M. Ibuprofen and meningoencephalitis. Ann Intern Med. 1984 Apr; 100 (4): 619. DOI: 10.7326/0003–4819–100–4–619_2.Lawson J. M., Grady M. J. Ibuprofen-induced aseptic meningitis in a previously healthy patient. West J Med. 1985 Sep; 143 (3): 386–7.Lawson J. M., Grady M. J. Ibuprofen-induced aseptic meningitis in a previously healthy patient. West J Med. 1985 Sep; 143 (3): 386–7.Katona B. G., Wigley F. M., Walters J. K., Caspi M. Aseptic meningitis from overthe-counter ibuprofen. Lancet. 1988 Jan 2–9; 1 (8575–6): 59. DOI: 10.1016/s0140–6736(88)91040–9.Katona B. G., Wigley F. M., Walters J. K., Caspi M. Aseptic meningitis from overthe-counter ibuprofen. Lancet. 1988 Jan 2–9; 1 (8575–6): 59. DOI: 10.1016/s0140–6736(88)91040–9.Jensen S., Glud T. K., Bacher T., Ersgaard H. Ibuprofen-induced meningitis in a male with systemic lupus erythematosus. Acta Med Scand. 1987; 221 (5): 509–11. DOI: 10.1111/j.0954–6820.1987.tb01289.x.Jensen S., Glud T. K., Bacher T., Ersgaard H. Ibuprofen-induced meningitis in a male with systemic lupus erythematosus. Acta Med Scand. 1987; 221 (5): 509–11. DOI: 10.1111/j.0954–6820.1987.tb01289.x.Ruppert G. B., Barth W. F. Tolmetin-induced aseptic meningitis. JAMA. 1981 Jan 2; 245 (1): 67–8.Ruppert G. B., Barth W. F. Tolmetin-induced aseptic meningitis. JAMA. 1981 Jan 2; 245 (1): 67–8.Ballas Z. K., Donta S. T. Sulindac-induced aseptic meningitis. Arch Intern Med. 1982 Jan; 142 (1): 165–6.Ballas Z. K., Donta S. T. Sulindac-induced aseptic meningitis. Arch Intern Med. 1982 Jan; 142 (1): 165–6.von Reyn C. F. Recurrent aseptic meningitis due to sulindac. Ann Intern Med. 1983 Sep; 99 (3): 343–4. DOI: 10.7326/0003–4819–99–3–343.von Reyn C. F. Recurrent aseptic meningitis due to sulindac. Ann Intern Med. 1983 Sep; 99 (3): 343–4. DOI: 10.7326/0003–4819–99–3–343.Yasuda Y., Akiguchi I., Kameyama M. Sulindac-induced aseptic meningitis in mixed connective tissue disease. Clin Neurol Neurosurg. 1989; 91 (3): 257–60. DOI: 10.1016/0303–8467(89)90121–2.Yasuda Y., Akiguchi I., Kameyama M. Sulindac-induced aseptic meningitis in mixed connective tissue disease. Clin Neurol Neurosurg. 1989; 91 (3): 257–60. DOI: 10.1016/0303–8467(89)90121–2.Greenberg G. N. Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs. South Med J 1988; 81: 1463–4.Greenberg G. N. Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs. South Med J 1988; 81: 1463–4.Hoppmann R. A., Peden J. G., Ober S. K. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Arch Intern Med 1991; 151: 1309–13.Hoppmann R. A., Peden J. G., Ober S. K. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Arch Intern Med 1991; 151: 1309–13.Marinac J. S. Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann Pharmacother 1992; 26: 813–22.Marinac J. S. Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann Pharmacother 1992; 26: 813–22.Batlouni M. Anti-inflamatórios não esteroides: Efeitos cardiovasculares, cérebro-vasculares e renais [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]. Arq Bras Cardiol. 2010 Apr; 94 (4): 556–63. Portuguese. DOI: 10.1590/s0066–782x2010000400019.Batlouni M. Anti-inflamatórios não esteroides: Efeitos cardiovasculares, cérebro-vasculares e renais [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]. Arq Bras Cardiol. 2010 Apr; 94 (4): 556–63. Portuguese. DOI: 10.1590/s0066–782x2010000400019.Yelehe-Okouma M., Czmil-Garon J., Pape E., Petitpain N., Gillet P. Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol. 2018 Jun; 32 (3): 252–260. DOI: 10.1111/fcp.12349.Yelehe-Okouma M., Czmil-Garon J., Pape E., Petitpain N., Gillet P. Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol. 2018 Jun; 32 (3): 252–260. DOI: 10.1111/fcp.12349.Goodwin J. S., Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982 Aug; 25 (8): 1013–5. DOI: 10.1002/art.1780250817.Goodwin J. S., Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982 Aug; 25 (8): 1013–5. DOI: 10.1002/art.1780250817.Browning C. H. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996; 26 (1): 25–34.Browning C. H. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996; 26 (1): 25–34.Jiang H. K., Chang D. M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18 (4): 339–45.Jiang H. K., Chang D. M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18 (4): 339–45.Onder G., Pellicciotti F., Gambassi G., Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs. 2004; 64 (23): 2619–27. DOI: 10.2165/00003495–200464230–00001.Onder G., Pellicciotti F., Gambassi G., Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs. 2004; 64 (23): 2619–27. DOI: 10.2165/00003495–200464230–00001.Wysenbeck A. J., Klein Z., Mane R. Assessment of cognitive function in elderly patients treated with naproxen: a prospective study. Clin Exp Rheumatol 1988; 6 (4): 399–400.Wysenbeck A. J., Klein Z., Mane R. Assessment of cognitive function in elderly patients treated with naproxen: a prospective study. Clin Exp Rheumatol 1988; 6 (4): 399–400.Kiesel E. K., Hopf Y. M., Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018 Oct 11; 18 (1): 239. DOI: 10.1186/s12877–018–0929–6.Kiesel E. K., Hopf Y. M., Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018 Oct 11; 18 (1): 239. DOI: 10.1186/s12877–018–0929–6.G. M. Rosa et al. 2013 Informa UK, Ltd. ISSN 1474–0338, e-ISSN 1744–764X.G. M. Rosa et al. 2013 Informa UK, Ltd. ISSN 1474–0338, e-ISSN 1744–764X.Cook S., Togni M., Schaub M. C., Wenaweser P., Hess O. M. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006 Oct; 27 (20): 2387–93. DOI: 10.1093/eurheartj/ehl259.Cook S., Togni M., Schaub M. C., Wenaweser P., Hess O. M. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006 Oct; 27 (20): 2387–93. DOI: 10.1093/eurheartj/ehl259.Majercak I. The use of heart rate variability in cardiology. Bratisl Lek Listy 2002; 103: 368–77.Majercak I. The use of heart rate variability in cardiology. Bratisl Lek Listy 2002; 103: 368–77.Полипрагмазия в клинической практике: проблема и решения. Учебное пособие. 2-е изд., испр. и доп. СПб.: ЦОП «Профессия», 2018. 272 с., ил.Polypharmacy in Clinical Practice: Problem and Solutions. Tutorial. 2nd ed., Rev. and add. SPb .: TsOP «Professiya», 2018. 272 p., Ill.Клинические рекомендации. Когнитивные расстройства у лиц пожилого и старческого возраста. Available at: http://cr.rosminzdrav.ru (дата обращения 25.11.2021).Clinical guidelines. Cognitive disorders in elderly and senile people. Available at: http://cr.rosminzdrav.ru (date of treatment 11/25/2021).Методические руководства «Фармакотерапия у лиц пожилого и старческого возраста» Available at: http://cr.rosminzdrav.ru (дата обращения 25.11.2021).Methodological guidelines «Pharmacotherapy in elderly and senile persons» Available at: http://cr.rosminzdrav.ru (date of treatment 11/25/2021).Carnahan R. M., Lund B. C., Perry P. J., Pollock B. G., Culp K. R. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006; 46: 1481–6.Carnahan R. M., Lund B. C., Perry P. J., Pollock B. G., Culp K. R. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006; 46: 1481–6.Han L., McCusker J., Cole M., Abrahamowicz M., Primeau F., Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161 (8): 1099–105.Han L., McCusker J., Cole M., Abrahamowicz M., Primeau F., Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161 (8): 1099–105.Государственный реестр лекарственных средств Минздрава России. Available at: https://grls.rosminzdrav.ru (дата обращения 25.11.2021).State Register of Medicines of the Ministry of Health of Russia. Available at: https://grls.rosminzdrav.ru (date of treatment 11/25/2021).Alagiakrishnan K., Wiens C. A. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004; 80 (945): 388–393. DOI: 10.1136/pgmj.2003.017236.Alagiakrishnan K., Wiens C. A. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004; 80 (945): 388–393. DOI: 10.1136/pgmj.2003.017236.Gupta D., Javali M., Pradeep R., Mehta A., Acharya P. T., Srinivasa R. Acute confusional state induced by diclofenac: Report and review of literature. Neurol India [serial online] 2019 [cited 2021 Nov 8]; 67: 858–61. Available from: https://www.neurologyindia.com/text.asp?2019/67/3/858/263243Gupta D., Javali M., Pradeep R., Mehta A., Acharya P. T., Srinivasa R. Acute confusional state induced by diclofenac: Report and review of literature. Neurol India [serial online] 2019 [cited 2021 Nov 8]; 67: 858–61. Available from: https://www.neurologyindia.com/text.asp?2019/67/3/858/263243Okumura A., Fukumoto Y., Hayakawa F., Nakano T., Higuchi K., Kamiya H., et al. Antipyretics and delirious behavior during febrile illness. Pediatr Int 2006; 48: 40–3.Okumura A., Fukumoto Y., Hayakawa F., Nakano T., Higuchi K., Kamiya H., et al. Antipyretics and delirious behavior during febrile illness. Pediatr Int 2006; 48: 40–3.Jain R., Agarwal A., Navjeet K. Delirium in immediate postoperative period in a patient operated for laparoscopic cholecystectomy: A case report. J Anesth Crit Care Open Access 2017; 8: 00314.Jain R., Agarwal A., Navjeet K. Delirium in immediate postoperative period in a patient operated for laparoscopic cholecystectomy: A case report. J Anesth Crit Care Open Access 2017; 8: 00314.Faaij R. A., Ziere G., Zietse R., Van der Cammen T. J. Delirium due to a drugdrug interaction of lithium and an NSAID. J Nutr Health Aging 2009; 13: 275–6.Faaij R. A., Ziere G., Zietse R., Van der Cammen T. J. Delirium due to a drugdrug interaction of lithium and an NSAID. J Nutr Health Aging 2009; 13: 275–6.eHealthMe. Diclofenac sodium and Delirium – from FDA reports. Available from: https://www.ehealthme.com/ds/diclofenac-sodium/delirium/eHealthMe. Diclofenac sodium and Delirium – from FDA reports. Available from: https://www.ehealthme.com/ds/diclofenac-sodium/delirium/Электронный ресурс для специалистов практического здравоохранения Drugbank. Available at: https://go.drugbank.com/drugs/DB06736. (дата обращения 25.11.2021).An electronic resource for practical health care professionals Drugbank. Available at: https://go.drugbank.com/drugs/DB06736. (date of treatment 11/25/2021).Электронный ресурс для специалистов практического здравоохранения Drug-safety-update. Available at: https://www.gov.uk/drug-safetyupdate/aceclofenac-preservex-updated-cardiovascular-advice-in-line-withdiclofenac-and-cox-2-inhibitors (дата обращения 25.11.2021).Electronic resource for practical healthcare professionals Drug-safety-update. Available at: https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox‑2-inhibitors (accessed 11/25/2021).Клинический протокол «Ведение пациентов пожилого и старческого возраста с высоким риском развития делирия при оказании медицинской помощи в стационарных условиях». Available at: https://www.volgmed.ru/uploads/files/2019–9/116006-vedenie_pacientov_s_riskom_deliriya.pdf (дата обращения 25.11.2021).Clinical protocol «Management of elderly and senile patients with a high risk of developing delirium in the provision of medical care in inpatient conditions.» Available at: https://www.volgmed.ru/uploads/files/2019–9/116006-vedenie_pacientov_s_riskom_deliriya.pdf (date accessed 11/25/2021).Остроумова О. Д., Исаев Р. И., Переверзев А. П. Лекарственно-индуцированная инсомния у пациентов пожилого и старческого возраста. Журнал неврологии и психиатрии им. С. С. Корсакова. 2019; 119 (8): 142–152.Ostroumova O. D., Isaev R. I., Pereverzev A. P. Drug-induced insomnia in elderly and senile patients. Journal of Neurology and Psychiatry. S. S. Korsakov. 2019; 119 (8): 142–152.Overeem S., Reading P. Sleep Disorders in Neurology: A Practical Approach. 2018. 360 p. DOI: 10.1002/9781118777251.Overeem S., Reading P. Sleep Disorders in Neurology: A Practical Approach. 2018. 360 p. DOI: 10.1002/9781118777251.Goverdhan P., Sravanthi A., Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2012; 2012: 974013. DOI: 10.1155/2012/974013.Goverdhan P., Sravanthi A., Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2012; 2012: 974013. DOI: 10.1155/2012/974013.Li H., Luo Y., Xu Y., Yang L., Hu C., Chen Q., Yang Y., Ma J., Zhang J., Xia H., Li Y., Yang J. Meloxicam Improves Cognitive Impairment of Diabetic Rats through COX2-PGE 2-EPs-cAMP/pPKA Pathway. Mol Pharm. 2018 Sep 4; 15 (9): 4121–4131. DOI: 10.1021/acs.molpharmaceut.8b00532.Li H., Luo Y., Xu Y., Yang L., Hu C., Chen Q., Yang Y., Ma J., Zhang J., Xia H., Li Y., Yang J. Meloxicam Improves Cognitive Impairment of Diabetic Rats through COX2-PGE 2-EPs-cAMP/pPKA Pathway. Mol Pharm. 2018 Sep 4; 15 (9): 4121–4131. DOI: 10.1021/acs.molpharmaceut.8b00532.Ianiski F. R., Alves C. B., Ferreira C. F. et al. Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer’s disease model in mice: involvement of Na+, K+-ATPase. Metab Brain Dis 31, 793–802 (2016). https://doi.org/10.1007/s11011–016–9812–3Ianiski F. R., Alves C. B., Ferreira C. F. et al. Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer’s disease model in mice: involvement of Na+, K+-ATPase. Metab Brain Dis 31, 793–802 (2016). https://doi.org/10.1007/s11011–016–9812–3Hakan T., Toklu H. Z., Biber N., Ozevren H., Solakoglu S., Demirturk P., Aker F. V. Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol Res. 2010 Jul; 32 (6): 629–35. DOI: 10.1179/016164109X12464612122731.Hakan T., Toklu H. Z., Biber N., Ozevren H., Solakoglu S., Demirturk P., Aker F. V. Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol Res. 2010 Jul; 32 (6): 629–35. DOI: 10.1179/016164109X12464612122731.

The authors declare that there are no conflicts of interest present.